Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul

This article was originally published in PharmAsia News

Executive Summary

The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.

You may also be interested in...

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

Citing Lack Of Infrastructure, Brakes Are Put On Allowing Phase I Trials In India

MUMBAI - After building great expectations on allowing Phase I human studies in India, the government has now back tracked from taking any concrete decisions until the "right infrastructure" is put in place

Drug Controller General Of India Surinder Singh On India’s Regulatory Overhaul: An Interview With PharmAsia News

Surinder Singh took the mantle of the Drug Controller General of India a few months ago. From being a microbiologist to handling the most important regulatory position in the Indian drug industry, Singh is already confronted with a host of challenges. Overhauling the regulatory system, dealing with vexatious registration issues and advocating for Indian drug industry on global forums, Singh has been working on an extremely tight schedule. Singh took time off from his busy routine and sat down with PharmAsia News' India bureau to discuss India's impending regulatory overhaul (PharmAsia News, Sept. 11, 2008).


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts